Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 8, Issue 2 (2019)

Clinical efficacy and safety of unani formulation for the management of Sharaa (Urticaria) - A case series study

A Khaleel Ahmed, Abdul Mobeen, Md. Anzar Alam and MA Quamri
In Unani Medicine urticaria is described as Sharaa. According to Ibn-e-Sina, Sharaa is a Damwi (sanguineous) disease usually but it may be arise due to Safravi Khoon (bilious blood) or Balgham-e-Boraqi (acidic phlegm). It appears as a Small and flat topped eruptions resembling vesicles (nifat), reddish in colour, with severe itching and pricking sensation and most often arise suddenly in the whole body. Ahmad Al-Tabari described that Sharaa (Urticaria) is caused either by Har hareef dam (Hot Saline blood) mix-up with Maktoobat-e-Fasida Ghaliza (morbid vicious humors) in small quantity or by mixing with Ratoobat-e-Raqiqa Fasida (morbid diluted humors) that become irritant due to Malahat (salinity).When Sharaa arise due to morbid humors represent with white, big maculae over the skin which comprise of Warm and humors inside it. Sometimes Sharaa occurs as result of mixing of Sanguine, Phlegm and Bile. In conventional Medicine Urticaria is generally treated with anti-histaminic drugs where as in Unani Medicine those drugs are beneficial which acts as Qat-e-Safra and evacuate (istefragh) the morbid material from the body like Gul-e-Surkh (Rosa damascena), Turbud (Operculina turpethum), Post Halela Zard (Terminalia chebula), Sana (Cassia angustifolia), Aloo Bukhara (Prunus domestica), Tamar Hindi (Tamarindus indica) etc. This case series study will be new approach for the management of Chronic Idiopathic Urticaria which is unresponsive to antihistamines and oral corticosteroids.
Pages: 454-455  |  616 Views  120 Downloads

The Pharma Innovation Journal
How to cite this article:
A Khaleel Ahmed, Abdul Mobeen, Md. Anzar Alam, MA Quamri. Clinical efficacy and safety of unani formulation for the management of <em>Sharaa </em>(Urticaria) - A case series study. Pharma Innovation 2019;8(2):454-455.

Call for book chapter